Constitutive or enhanced signaling of this pathway is common in thyroid cancer (44, 45), and elevated AKT activity has been associated with tumor size and invasion in both FTC and PTC, with the exception of tumors with BRAF activating mutations (44). The gene discussed is BRAF; the disease is thyroid cancer, nonmedullary, 2.